Alzamend Neuro Inc. will hold its 2026 Annual Meeting of Stockholders on April 17, 2026. During the meeting, shareholders will vote on several key proposals, including the election of seven directors, the ratification of the appointment of Haskell & White LLP as the company’s independent registered public accounting firm for the fiscal year ending April 30, 2026, a non-binding advisory vote on compensation paid to named executive officers, approval of the company’s 2025 Equity Incentive Plan, approval of equity issuances to directors and executive officers, and approval of an amendment to the company’s Certificate of Incorporation to effect a reverse stock split of the company’s common stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alzamend Neuro Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001214659-26-001345), on February 09, 2026, and is solely responsible for the information contained therein.